Exelixis Inc (EXEL)
NASDAQ · Healthcare · Biotechnology
Exelixis Inc is a Healthcare company with a market capitalization of $13.77B and a trailing P/E ratio of 18.1.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 5, 2026 | $0.87 | $0.76 | +14.5% |
| Q4 2025 | February 10, 2026 | $0.88 | $0.75 | +17.3% |
| Q3 2025 | November 4, 2025 | $0.78 | $0.67 | +16.4% |
| Q2 2025 | July 28, 2025 | $0.75 | $0.65 | +15.4% |
| Q1 2025 | May 13, 2025 | $0.62 | $0.37 | +69.1% |
| Q4 2024 | February 11, 2025 | $0.55 | $0.49 | +12.2% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Exelixis Inc's market cap?
As of June 29, 2026, Exelixis Inc (EXEL) has a market capitalization of $13.77B.
What is Exelixis Inc's P/E ratio?
Exelixis Inc trades at a trailing price-to-earnings (P/E) ratio of 18.1. Its forward P/E is 16.8.
Does Exelixis Inc pay a dividend?
Exelixis Inc does not currently pay a dividend.
What sector is EXEL in?
Exelixis Inc is in the Healthcare sector, specifically the Biotechnology industry.
What was Exelixis Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Exelixis Inc reported revenue of $2.32B and net income of $782.57M.
Ask your own questions about EXEL
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.